Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis
Identifieur interne : 001F64 ( Main/Exploration ); précédent : 001F63; suivant : 001F65Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis
Auteurs : M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J Blanchet [Canada] ; P. Falardeau [Canada] ; P. J Bédard [Canada] ; T. Di Paolo [Canada]Source :
- Neuroscience [ 0306-4522 ] ; 1996.
Abstract
The effect of a chronic D2 dopamine receptor agonist (U91356A) treatment on dopamine receptor gene expression in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys was investigated using quantitative in situ hybridization histochemistry. U91356A was administered to MPTP-monkeys for 27 days in a pulsatile (n=3) or continuous (n=3) schedule. Animals treated in a pulsatile mode showed progressive sensitization and developed dyskinesia; whereas with the continuous mode behavioural tolerance was observed but no dyskinesia developed. Untreated MPTP as well as naive control animals were also studied. The efficacy and uniformity of the MPTP effect was assessed by measures of dopamine concentrations by high performance liquid chromatography with electrochemical detection in the relevant brain areas. D1 and D2 receptor messenger RNAs levels were examined by in situ hybridization histochemistry using human complementary RNA probes. Intense specific labelling for D1 and D2 receptor messenger RNAs was measured in the caudate and putamen with a rostrocaudal gradient for D2 receptors and a lower density in the cortex for D1 receptors messenger RNA. D1 receptor mRNA levels in rostral striatum and cortex decreased whereas D2 receptor messenger RNA in caudal striatum increased in MPTP-monkeys compared to control animals. Continuous administration of U91356A reversed the MPTP-induced increase of D2 receptor messenger RNA, whereas the pulsatile administration did not significantly correct these messenger RNA changes. U91356A treatment whether continuous or pulsatile partially corrected the D1 receptor messenger RNA lesion-induced decrease in the striatum, whereas no correction was observed in the cortex. All MPTP-monkeys were extensively and similarly denervated suggesting that the D1 and D2 receptor expression changes following U91356A administration were treatment related. Our data show a lesion-induced imbalance of D1 (decrease) and D2 (increase) receptor messenger RNAs in the striatum of MPTP-monkeys. The response of these receptors to D2 agonist treatment showed receptor selectivity and was influenced by the time-course of drug delivery. Hence chronic continuous but not pulsatile administration of U91356A reversed the striatal D2 receptor messenger RNA increase.
Url:
DOI: 10.1016/S0306-4522(96)00689-6
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M" last="Goulet">M. Goulet</name></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name></author><author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J" last="Blanchet">P. J Blanchet</name></author><author><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P" last="Falardeau">P. Falardeau</name></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J" last="Bédard">P. J Bédard</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32DB2B3775F76D5DCF33E9B9F3AD029FEB733AB5</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0306-4522(96)00689-6</idno><idno type="url">https://api.istex.fr/document/32DB2B3775F76D5DCF33E9B9F3AD029FEB733AB5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002298</idno><idno type="wicri:Area/Main/Curation">001F82</idno><idno type="wicri:Area/Main/Exploration">001F64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis</title><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M" last="Goulet">M. Goulet</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Centre, Enfant-Jesus Hospital, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J" last="Blanchet">P. J Blanchet</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Centre, Enfant-Jesus Hospital, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P" last="Falardeau">P. Falardeau</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Department of Molecular and Genetic Medecine, Laval University Medical Centre, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J" last="Bédard">P. J Bédard</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Centre, Enfant-Jesus Hospital, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Department of Molecular Endocrinology, Laval University Medical Centre, Ste-Foy, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation><affiliation><wicri:noCountry code="no comma">To whom correspondence should be addressed.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Neuroscience</title><title level="j" type="abbrev">NSC</title><idno type="ISSN">0306-4522</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">79</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="497">497</biblScope><biblScope unit="page" to="507">507</biblScope></imprint><idno type="ISSN">0306-4522</idno></series><idno type="istex">32DB2B3775F76D5DCF33E9B9F3AD029FEB733AB5</idno><idno type="DOI">10.1016/S0306-4522(96)00689-6</idno><idno type="PII">S0306-4522(96)00689-6</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0306-4522</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effect of a chronic D2 dopamine receptor agonist (U91356A) treatment on dopamine receptor gene expression in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys was investigated using quantitative in situ hybridization histochemistry. U91356A was administered to MPTP-monkeys for 27 days in a pulsatile (n=3) or continuous (n=3) schedule. Animals treated in a pulsatile mode showed progressive sensitization and developed dyskinesia; whereas with the continuous mode behavioural tolerance was observed but no dyskinesia developed. Untreated MPTP as well as naive control animals were also studied. The efficacy and uniformity of the MPTP effect was assessed by measures of dopamine concentrations by high performance liquid chromatography with electrochemical detection in the relevant brain areas. D1 and D2 receptor messenger RNAs levels were examined by in situ hybridization histochemistry using human complementary RNA probes. Intense specific labelling for D1 and D2 receptor messenger RNAs was measured in the caudate and putamen with a rostrocaudal gradient for D2 receptors and a lower density in the cortex for D1 receptors messenger RNA. D1 receptor mRNA levels in rostral striatum and cortex decreased whereas D2 receptor messenger RNA in caudal striatum increased in MPTP-monkeys compared to control animals. Continuous administration of U91356A reversed the MPTP-induced increase of D2 receptor messenger RNA, whereas the pulsatile administration did not significantly correct these messenger RNA changes. U91356A treatment whether continuous or pulsatile partially corrected the D1 receptor messenger RNA lesion-induced decrease in the striatum, whereas no correction was observed in the cortex. All MPTP-monkeys were extensively and similarly denervated suggesting that the D1 and D2 receptor expression changes following U91356A administration were treatment related. Our data show a lesion-induced imbalance of D1 (decrease) and D2 (increase) receptor messenger RNAs in the striatum of MPTP-monkeys. The response of these receptors to D2 agonist treatment showed receptor selectivity and was influenced by the time-course of drug delivery. Hence chronic continuous but not pulsatile administration of U91356A reversed the striatal D2 receptor messenger RNA increase.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M" last="Goulet">M. Goulet</name></noRegion><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J" last="Bédard">P. J Bédard</name><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J" last="Blanchet">P. J Blanchet</name><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name><name sortKey="Falardeau, P" sort="Falardeau, P" uniqKey="Falardeau P" first="P" last="Falardeau">P. Falardeau</name><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:32DB2B3775F76D5DCF33E9B9F3AD029FEB733AB5
|texte= Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis
}}
| This area was generated with Dilib version V0.6.23. |  |